Skip to main content

Table 1 Baseline characteristics of patients who underwent THA before and after 1:1 propensity score matchinga

From: The impact of systemic lupus erythematosus on the risk of infection after total hip arthroplasty: a nationwide population-based matched cohort study

  Before match   After match  
SLE Control P value SLE Control P value
(n = 617) (n = 2414) (n = 325) (n = 325)
Age 38.7 ± 12.7 56.7 ± 14.5 < 0.01 44.3 ± 12.0 46.1 ± 14.0 0.07
Female 503 (81.5%) 999 (41.4%) < 0.01 237 (72.9%) 237 (72.9%) 1.00
Comorbidities
 Cerebral vascular accidents 39 (6.3%) 247 (10.2%) < 0.01 27 (8.3%) 17 (5.2%) 0.11
 Coronary heart disease 46 (7.5%) 412 (17.1%) < 0.01 45 (13.8%) 35 (10.7%) 0.09
 Congestive heart failure 38 (6.2%) 120 (5%) 0.26 19 (5.8%) 11 (3.4%) 0.13
 Chronic obstructive pulmonary disease 59 (9.6%) 320 (13.3%) < 0.01 43 (13.2%) 35 (10.8%) 0.11
 Diabetes mellitus 28 (4.5%) 450 (18.6%) < 0.01 27 (8.3%) 22 (6.8%) 0.45
 Cirrhosis 7 (1.1%) 122 (5.1%) < 0.01 3 (0.9%) 5 (1.5%) 0.48
 Chronic kidney disease 87 (14.1%) 71 (2.9%) < 0.01 29 (8.9%) 20 (6.2%) 0.10
 Dialysis 30 (4.9%) 13 (0.5%) < 0.01 9 (2.8%) 5 (1.5%) 0.28
CCI_Score 2.49 ± 1.51 1.58 ± 1.78 < 0.01 2.37 ± 1.42 1.36 ± 1.71 < 0.01
  1. CCI Charlson comorbidity index, SLE systemic lupus erythematosus
  2. aData are presented as number and percentage or mean ± standard deviation